vida: extract claims from 2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025

- Source: inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md

@@ -31,3 +31,10 @@ Exenatide Phase 3 showed no DaT-SPECT signal change versus placebo, meaning the
 **Source:** Holscher 2024 review + exenatide Phase 3 CSF data (Lancet Feb 2025)
 
 Exenatide Phase 3 CSF analysis revealed that BBB crossing (a pharmacokinetic surrogate) doesn't predict substantia nigra penetrance (the therapeutic target). Only small amounts reached affected brain areas despite documented BBB penetrance, explaining Phase 2 success (general neuroprotection) versus Phase 3 failure (insufficient regional delivery).
+
+
+## Supporting Evidence
+
+**Source:** PMC12374370 meta-analysis 2025
+
+Updated meta-analysis (5 RCTs, n=708) shows MDS-UPDRS Part III improvement of only -2.06 points (95% CI -4.09 to -0.03)—statistically significant but clinically marginal. No improvement in MDS-UPDRS Parts I, II, IV, no levodopa dose reduction, no PDQ-39 quality of life improvement, and no Non-Motor Symptoms Scale improvement. This confirms that motor biomarker changes do not translate to functional benefit in Parkinson's GLP-1 trials.

domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md

@@ -38,3 +38,10 @@ GLP-1 receptor expression in ventral tegmental area (VTA) and nucleus accumbens
 **Source:** LIXIPARK NEJM April 2024
 
 LIXIPARK demonstrated motor symptom stabilization in early Parkinson's disease (dopaminergic neurodegeneration) at 12 months, challenging the blanket claim that GLP-1s fail in neurodegeneration. However, this is Phase 2 in early disease only, and the lack of Phase 3 funding post-publication suggests the field remains skeptical. The divergence from exenatide Phase 3 failure indicates disease stage and drug-specific penetrance may be boundary conditions.
+
+
+## Extending Evidence
+
+**Source:** PMC12374370 + Lancet exenatide Phase 3 Feb 2025
+
+Exenatide Phase 3 failure (Lancet Feb 2025) with CSF analysis showing BBB crossing but insufficient substantia nigra penetrance provides mechanistic explanation: GLP-1 agonists succeed in reward circuits (VTA, nucleus accumbens) but fail in neurodegeneration (substantia nigra) due to regional CNS access differences, not circuit-specific receptor distribution. Lixisenatide Phase 2 success suggests within-class variation in regional penetrance.

domains/health/loneliness-increases-dementia-risk-50-percent-independently-of-depression-and-cardiovascular-disease.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-05-08-who-commission-social-connection-june-2025.md
 scope: causal
 sourcer: World Health Organization
 supports: ["social-isolation-costs-medicare-7-billion-annually-and-carries-mortality-risk-equivalent-to-smoking-15-cigarettes-per-day-making-loneliness-a-clinical-condition-not-a-personal-problem"]
-related: ["semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment", "social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem"]
+related: ["semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment", "social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem", "loneliness-increases-dementia-risk-50-percent-independently-of-depression-and-cardiovascular-disease"]
 ---
 
 # Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy
 
 The WHO Commission on Social Connection's 3-year investigation found that loneliness and social isolation increase dementia risk by 50 percent. This effect operates independently of depression and cardiovascular disease pathways, establishing social disconnection as a direct neurological risk factor rather than a proxy for other conditions. The magnitude of this effect (50% increased risk) exceeds the cardiovascular signals (32% stroke, 29% heart disease) and suggests social isolation may be a significant contributor to the dementia epidemic. This finding has immediate policy implications: if social isolation increases dementia risk by 50%, and pharmacological interventions like GLP-1 receptor agonists show no clinical benefit in Alzheimer's (as demonstrated in the EVOKE trial failure), then addressing loneliness represents a more powerful anti-dementia intervention than current drug development pipelines. The mechanism appears to be direct rather than mediated—social connection affects cognitive reserve, neuroplasticity, and inflammatory pathways that protect against neurodegeneration. The WHO report establishes this as a global pattern across 193 member nations, with 1 in 6 people experiencing persistent loneliness.
+
+
+## Challenging Evidence
+
+**Source:** PMC11722644, coordinated meta-analysis, 21 studies
+
+Meta-analysis of 608,561 individuals finds loneliness increases dementia risk by 19-31% (not 50%), with depression adjustment reducing HR from 1.306 to 1.189 (not to null), indicating partial rather than complete independence from depression. CVD adjustment shows negligible effect, confirming independence from cardiovascular pathways.

domains/health/loneliness-independently-increases-dementia-risk-19-31-percent-after-depression-adjustment-with-vascular-dementia-showing-strongest-association.md

@@ -0,0 +1,26 @@
+---
+type: claim
+domain: health
+description: Meta-analysis of 608,561 individuals finds loneliness retains significant dementia association after controlling for depression (HR 1.189) and cardiovascular factors (negligible effect), with vascular dementia (HR 1.735) exceeding Alzheimer's (HR 1.393)
+confidence: likely
+source: Coordinated meta-analysis, PMC11722644, 21 studies, N=608,561
+created: 2026-05-09
+title: "Loneliness independently increases all-cause dementia risk by 19-31% after adjusting for depression, with vascular dementia showing stronger association than Alzheimer's disease"
+agent: vida
+sourced_from: health/2026-05-09-pmc11722644-loneliness-dementia-meta-analysis-600k.md
+scope: causal
+sourcer: PMC11722644
+supports: ["social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+challenges: ["loneliness-increases-dementia-risk-50-percent-independently-of-depression-and-cardiovascular-disease"]
+related: ["loneliness-increases-dementia-risk-50-percent-independently-of-depression-and-cardiovascular-disease", "social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+---
+
+# Loneliness independently increases all-cause dementia risk by 19-31% after adjusting for depression, with vascular dementia showing stronger association than Alzheimer's disease
+
+This meta-analysis resolves the critical question of whether social isolation's dementia association operates independently of depression and cardiovascular disease. The unadjusted hazard ratio of 1.306 (95% CI 1.197-1.426) attenuates to 1.189 (95% CI 1.101-1.285) after controlling for both depression AND social isolation — a 9% reduction that leaves the association statistically significant. This demonstrates loneliness has an independent relationship with dementia beyond depressive symptoms.
+
+Crucially, including cardiovascular risk factors (diabetes, hypertension, obesity) had "negligible effect" on the associations, suggesting CVD is NOT a primary mediating pathway. This contradicts the expected mechanism where social isolation → CVD → dementia, and instead supports direct neuroinflammatory or stress-mediated pathways.
+
+The cause-specific analysis reveals differential effects: Alzheimer's disease HR = 1.393 (95% CI 1.290-1.504) versus vascular dementia HR = 1.735 (95% CI 1.483-2.029). The stronger vascular dementia association suggests inflammatory/vascular mechanisms rather than amyloid/tau pathways as the primary mediator.
+
+This evidence base is stronger than prior estimates: the WHO's "50% elevated risk" figure comes from specific social frailty studies, while this larger, more rigorous analysis gives 19-31% depending on adjustment strategy. The persistence of effect after depression adjustment establishes loneliness as a dementia risk factor operating through mechanisms beyond mood disorders.

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -99,3 +99,10 @@ Topics:
 **Source:** Papanicolas et al., JAMA Internal Medicine 2025
 
 The 3:1 ratio of preventable (24.3 per 100,000) to treatable (7.5 per 100,000) mortality increase from 2009-2019 provides direct empirical evidence that behavioral and social determinants dominate over clinical care factors in US health outcomes. The spending-mortality correlation breakdown (-0.12 in US states vs -0.7 in peer nations) demonstrates that clinical spending cannot address the primary drivers of US mortality deterioration.
+
+
+## Supporting Evidence
+
+**Source:** PMC11722644, meta-analysis controlling for CVD factors
+
+Loneliness → dementia association shows negligible attenuation when controlling for cardiovascular risk factors (diabetes, hypertension, obesity), demonstrating social determinants operate through pathways independent of traditional clinical risk factors in dementia pathogenesis.

domains/health/social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem.md

@@ -1,14 +1,13 @@
 ---
-description: Surgeon General declared loneliness a public health crisis in 2023 with mortality risk exceeding obesity and social prescribing pilots in Massachusetts show 4.43 dollar ROI per dollar invested but US infrastructure for connecting patients to community resources barely exists
 type: claim
 domain: health
-created: 2026-02-17
-source: "HHS Surgeon General social connection advisory 2023; National Academies social isolation Medicare cost 2023; Lancet Public Health social prescribing landscape US 2025; Mass Cultural Council CultureRx ROI data"
+description: Surgeon General declared loneliness a public health crisis in 2023 with mortality risk exceeding obesity and social prescribing pilots in Massachusetts show 4.43 dollar ROI per dollar invested but US infrastructure for connecting patients to community resources barely exists
 confidence: likely
-supports:
-- Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy
-reweave_edges:
-- Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy|supports|2026-05-09
+source: HHS Surgeon General social connection advisory 2023; National Academies social isolation Medicare cost 2023; Lancet Public Health social prescribing landscape US 2025; Mass Cultural Council CultureRx ROI data
+created: 2026-02-17
+supports: ["Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy"]
+reweave_edges: ["Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy|supports|2026-05-09"]
+related: ["social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem"]
 ---
 
 # social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem
@@ -52,4 +51,10 @@ Relevant Notes:
 - Devoted democratizes VIP-level care by assigning every member a hybrid AI-human care team with digital twins and hundreds of daily interactions -- Devoted's care model explicitly includes loneliness reduction as a care function, addressing the $6.7B cost driver through persistent human+AI connection
 
 Topics:
-- health and wellness
+- health and wellness
+
+## Extending Evidence
+
+**Source:** PMC11722644, N=608,561 across 21 studies
+
+Loneliness independently increases all-cause dementia risk (HR 1.189 after depression adjustment) with vascular dementia showing strongest association (HR 1.735), establishing dementia as a specific clinical outcome pathway beyond general mortality risk. Effect persists after CVD adjustment, suggesting non-cardiovascular mechanisms.

entities/health/most-able-trial.md

@@ -0,0 +1,39 @@
+---
+type: entity
+entity_type: research_program
+name: MOST-ABLE Trial
+full_name: Oral Semaglutide for Parkinson's Disease Motor Symptoms Trial
+domain: health
+status: active
+---
+
+# MOST-ABLE Trial
+
+**Type:** Phase 2/3 randomized controlled trial  
+**Intervention:** Oral semaglutide 7mg and 14mg daily  
+**Population:** n=99 patients with Parkinson's disease  
+**Location:** Japan  
+**Primary Endpoint:** Motor symptom improvement (MDS-UPDRS Part III)  
+
+## Overview
+
+MOST-ABLE is the first randomized controlled trial testing semaglutide specifically for Parkinson's disease motor symptoms. Unlike prior GLP-1 Parkinson's trials (exenatide, liraglutide, lixisenatide), this study uses oral semaglutide, which has a distinct CNS access mechanism via tanycytes targeting hypothalamus and brainstem regions.
+
+## Significance
+
+The trial addresses a critical evidence gap: all prior GLP-1 Parkinson's RCTs used older GLP-1 agonists with different CNS penetrance profiles. Exenatide's Phase 3 failure (Lancet Feb 2025) revealed that blood-brain barrier crossing does not guarantee substantia nigra penetrance. Semaglutide's tanycyte-mediated CNS access may provide superior regional distribution, but this remains empirically unproven.
+
+## Timeline
+
+- **2024** — Protocol published, enrollment completed
+- **Nov-Dec 2025** — Data collection completed
+- **2026** — Results expected (as of May 2026, publication pending)
+
+## Context
+
+Meta-analysis of 5 prior GLP-1 Parkinson's RCTs (n=708) shows narrow motor benefit (MDS-UPDRS Part III -2.06, 95% CI -4.09 to -0.03) but no functional quality of life improvement. MOST-ABLE results will determine whether semaglutide's distinct CNS access mechanism translates to superior clinical efficacy.
+
+## Sources
+
+- PMC12374370 meta-analysis (Jan 2025)
+- Session 40 GLP-1 Parkinson's divergence analysis (May 2026)

inbox/archive/health/2026-05-09-pmc11722644-loneliness-dementia-meta-analysis-600k.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: research
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-09
 priority: high
 tags: [loneliness, social-isolation, dementia, Alzheimer's, vascular-dementia, meta-analysis, depression-mediation, non-clinical-determinants]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: research
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-09
 priority: medium
 tags: [GLP-1, Parkinson's-disease, meta-analysis, semaglutide, exenatide, lixisenatide, neuroprotection, motor-symptoms]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/null-result/2026-05-09-pmc12676184-mendelian-randomization-dementia-risk-factors-review.md

@@ -7,10 +7,11 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: research
-status: unprocessed
+status: null-result
 priority: high
 tags: [Mendelian-randomization, dementia, social-isolation, causal-inference, Lancet-Commission, evidence-quality, non-clinical-determinants]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content